Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Rahul Banerjee; Vinay Prasad

doi:10.1038/s41571-020-00448-y

Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19

Nat Rev Clin Oncol. 2021 Jan;18(1):7-8. doi: 10.1038/s41571-020-00448-y.

Authors

Rahul Banerjee¹, Vinay Prasad^{2

3

4}

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
² Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. vinayak.prasad@ucsf.edu.
³ Department of Epidemiology and Biostatistics, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. vinayak.prasad@ucsf.edu.
⁴ Department of Hematology Oncology, San Francisco General Hospital, San Francisco, CA, USA. vinayak.prasad@ucsf.edu.

Abstract

Randomized controlled trials designed to test cancer therapies often fail to clarify effectiveness in real-world settings. Herein, we explore lessons for trial development in oncology that can be learnt from the large-cohort, pragmatic RECOVERY trial involving patients hospitalized with COVID-19.

Publication types

Comment

MeSH terms

Anti-Inflammatory Agents / therapeutic use
COVID-19 Drug Treatment*
Dexamethasone* / therapeutic use
Humans
Inpatients
Oncologists
SARS-CoV-2

Substances

Anti-Inflammatory Agents
Dexamethasone